cabazitaxel stada
stada arzneimittel ag - kabazitakselis - koncentratas infuziniam tirpalui - 20 mg/ml - cabazitaxel
erivedge
roche registration gmbh - vismodegib - karcinoma, bazinė ląstelė - antinavikiniai vaistai - erivedge fluorouracilu gydyti suaugusiems pacientams, sergantiems:- simptominė metastazavusiu bazalioma - lokaliai išplitusio bazalioma netinkamas operacijos ar spindulinio.
clarithromycin-teva
teva pharma b.v. - klaritromicinas - plėvele dengtos tabletės - 250 mg; 500 mg - clarithromycin
qinlock
deciphera pharmaceuticals (netherlands) b.v. - ripretinib - virškinimo trakto stromos navikai - antinavikiniai vaistai - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.
resthizen
zenthique limited - klaritromicinas - milteliai infuzinio tirpalo koncentratui - 500 mg - clarithromycin
teriflunomide zentiva
zentiva k.s. - teriflunomidas - plėvele dengtos tabletės - 14 mg - teriflunomide
teriflunomide teva
teva b.v. - teriflunomidas - plėvele dengtos tabletės - 14 mg - teriflunomide
aregalu
krka, d.d., novo mesto - teriflunomidas - plėvele dengtos tabletės - 14 mg - teriflunomide
terebyo
sandoz d.d. - teriflunomidas - plėvele dengtos tabletės - 14 mg - teriflunomide
kaftrio
vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.